ICB therapy is beneficial for patients with PD-L1-negative tumors, including NSCLC, kidney cancer, and other tumors, potentially owing to higher mutational and neoantigen load, possibly because of the heterogeneous expression of PD-L1 in the TME and distinct tumor histology (47, 48). This evidence concerns the gene CD274 and non-small cell lung carcinoma.